These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 30634925)

  • 1. Correlate tumor mutation burden with immune signatures in human cancers.
    Wang X; Li M
    BMC Immunol; 2019 Jan; 20(1):4. PubMed ID: 30634925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.
    Jiang Z; Liu Z; Li M; Chen C; Wang X
    EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
    Li M; Gao X; Wang X
    Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.
    Raj SKS; Routh ED; Chou JW; Votanopoulos KI; Triozzi PL; Miller LD
    Cancer; 2022 Sep; 128(17):3254-3264. PubMed ID: 35767280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
    Luo C; Chen J; Chen L
    Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
    Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
    Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Value of Tumor Mutation Burden and Immune Cell Infiltration in Thymic Epithelial Tumors.
    Du H; Xie S; Guo W; Zhang W; Che J; Zhu L; Hang J
    Ann Clin Lab Sci; 2021 Jan; 51(1):44-54. PubMed ID: 33653780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
    Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
    Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
    Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
    Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 16. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
    Lin J; Lin Y; Huang Z; Li X
    Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
    Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
    Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
    J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.